Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas

Mee Chou Kiu, Chen Nen Chang, Wan Chun Cheng, Tzu Kang Lin, Cheuk Wah Wong, Simon G. Tang, Wai Man Leung, Li Hui Chen, Yet Sen Ho, Kim Thean Ng, Jen Shi Chen, Tsai Hsen Yang, Gi Ming Lai

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Twenty-two patients, aged 16 to 67, who had malignant gliomas after surgical resection were treated with carmustine and cisplatin intravenous infusion before, during, and after radiotherapy. All patients had subtotal or total resection, or biopsy as the initial procedure. Twenty-one patients who had at least 2 cycles of chemotherapy and finished the whole course of radiotherapy were considered to be evaluable for responses. Among them, 5 had glioblastoma multiforme, 16 had anaplastic astrocytoma. The median time to tumor progression was 35 weeks (range 12-130 weeks) and median survival time was 66 weeks (range 10-156 weeks). Early progression occurred more frequently in patients with biopsy only and subtotal resection, and in patients with glioblastoma than in those with anaplastic astrocytoma. This combined modality treatment program was associated with reversible hematologic toxicity which was severe in 2 patients, and with ototoxicity in 1 patient, nephrotoxicity in 2 patients. Combination of carmustine and cisplatin with cranial irradiation for malignant gliomas is moderately toxic and appears to offer no obvious survival advantage compared with radiation therapy plus BCNU alone.

Original languageEnglish
Pages (from-to)215-220
Number of pages6
JournalJournal of Neuro-Oncology
Volume25
Issue number3
DOIs
Publication statusPublished - Oct 1995
Externally publishedYes

Fingerprint

Carmustine
Combination Drug Therapy
Glioma
Cisplatin
Radiotherapy
Astrocytoma
Glioblastoma
Cranial Irradiation
Biopsy
Survival
Poisons
Intravenous Infusions
Drug Therapy

Keywords

  • carmustine
  • chemotherapy
  • cisplatin
  • malignant glioma

ASJC Scopus subject areas

  • Neuroscience(all)
  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas. / Kiu, Mee Chou; Chang, Chen Nen; Cheng, Wan Chun; Lin, Tzu Kang; Wong, Cheuk Wah; Tang, Simon G.; Leung, Wai Man; Chen, Li Hui; Ho, Yet Sen; Ng, Kim Thean; Chen, Jen Shi; Yang, Tsai Hsen; Lai, Gi Ming.

In: Journal of Neuro-Oncology, Vol. 25, No. 3, 10.1995, p. 215-220.

Research output: Contribution to journalArticle

Kiu, MC, Chang, CN, Cheng, WC, Lin, TK, Wong, CW, Tang, SG, Leung, WM, Chen, LH, Ho, YS, Ng, KT, Chen, JS, Yang, TH & Lai, GM 1995, 'Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas', Journal of Neuro-Oncology, vol. 25, no. 3, pp. 215-220. https://doi.org/10.1007/BF01053154
Kiu, Mee Chou ; Chang, Chen Nen ; Cheng, Wan Chun ; Lin, Tzu Kang ; Wong, Cheuk Wah ; Tang, Simon G. ; Leung, Wai Man ; Chen, Li Hui ; Ho, Yet Sen ; Ng, Kim Thean ; Chen, Jen Shi ; Yang, Tsai Hsen ; Lai, Gi Ming. / Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas. In: Journal of Neuro-Oncology. 1995 ; Vol. 25, No. 3. pp. 215-220.
@article{dcd3664c256649868a48daab170557ec,
title = "Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas",
abstract = "Twenty-two patients, aged 16 to 67, who had malignant gliomas after surgical resection were treated with carmustine and cisplatin intravenous infusion before, during, and after radiotherapy. All patients had subtotal or total resection, or biopsy as the initial procedure. Twenty-one patients who had at least 2 cycles of chemotherapy and finished the whole course of radiotherapy were considered to be evaluable for responses. Among them, 5 had glioblastoma multiforme, 16 had anaplastic astrocytoma. The median time to tumor progression was 35 weeks (range 12-130 weeks) and median survival time was 66 weeks (range 10-156 weeks). Early progression occurred more frequently in patients with biopsy only and subtotal resection, and in patients with glioblastoma than in those with anaplastic astrocytoma. This combined modality treatment program was associated with reversible hematologic toxicity which was severe in 2 patients, and with ototoxicity in 1 patient, nephrotoxicity in 2 patients. Combination of carmustine and cisplatin with cranial irradiation for malignant gliomas is moderately toxic and appears to offer no obvious survival advantage compared with radiation therapy plus BCNU alone.",
keywords = "carmustine, chemotherapy, cisplatin, malignant glioma",
author = "Kiu, {Mee Chou} and Chang, {Chen Nen} and Cheng, {Wan Chun} and Lin, {Tzu Kang} and Wong, {Cheuk Wah} and Tang, {Simon G.} and Leung, {Wai Man} and Chen, {Li Hui} and Ho, {Yet Sen} and Ng, {Kim Thean} and Chen, {Jen Shi} and Yang, {Tsai Hsen} and Lai, {Gi Ming}",
year = "1995",
month = "10",
doi = "10.1007/BF01053154",
language = "English",
volume = "25",
pages = "215--220",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas

AU - Kiu, Mee Chou

AU - Chang, Chen Nen

AU - Cheng, Wan Chun

AU - Lin, Tzu Kang

AU - Wong, Cheuk Wah

AU - Tang, Simon G.

AU - Leung, Wai Man

AU - Chen, Li Hui

AU - Ho, Yet Sen

AU - Ng, Kim Thean

AU - Chen, Jen Shi

AU - Yang, Tsai Hsen

AU - Lai, Gi Ming

PY - 1995/10

Y1 - 1995/10

N2 - Twenty-two patients, aged 16 to 67, who had malignant gliomas after surgical resection were treated with carmustine and cisplatin intravenous infusion before, during, and after radiotherapy. All patients had subtotal or total resection, or biopsy as the initial procedure. Twenty-one patients who had at least 2 cycles of chemotherapy and finished the whole course of radiotherapy were considered to be evaluable for responses. Among them, 5 had glioblastoma multiforme, 16 had anaplastic astrocytoma. The median time to tumor progression was 35 weeks (range 12-130 weeks) and median survival time was 66 weeks (range 10-156 weeks). Early progression occurred more frequently in patients with biopsy only and subtotal resection, and in patients with glioblastoma than in those with anaplastic astrocytoma. This combined modality treatment program was associated with reversible hematologic toxicity which was severe in 2 patients, and with ototoxicity in 1 patient, nephrotoxicity in 2 patients. Combination of carmustine and cisplatin with cranial irradiation for malignant gliomas is moderately toxic and appears to offer no obvious survival advantage compared with radiation therapy plus BCNU alone.

AB - Twenty-two patients, aged 16 to 67, who had malignant gliomas after surgical resection were treated with carmustine and cisplatin intravenous infusion before, during, and after radiotherapy. All patients had subtotal or total resection, or biopsy as the initial procedure. Twenty-one patients who had at least 2 cycles of chemotherapy and finished the whole course of radiotherapy were considered to be evaluable for responses. Among them, 5 had glioblastoma multiforme, 16 had anaplastic astrocytoma. The median time to tumor progression was 35 weeks (range 12-130 weeks) and median survival time was 66 weeks (range 10-156 weeks). Early progression occurred more frequently in patients with biopsy only and subtotal resection, and in patients with glioblastoma than in those with anaplastic astrocytoma. This combined modality treatment program was associated with reversible hematologic toxicity which was severe in 2 patients, and with ototoxicity in 1 patient, nephrotoxicity in 2 patients. Combination of carmustine and cisplatin with cranial irradiation for malignant gliomas is moderately toxic and appears to offer no obvious survival advantage compared with radiation therapy plus BCNU alone.

KW - carmustine

KW - chemotherapy

KW - cisplatin

KW - malignant glioma

UR - http://www.scopus.com/inward/record.url?scp=0028867792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028867792&partnerID=8YFLogxK

U2 - 10.1007/BF01053154

DO - 10.1007/BF01053154

M3 - Article

C2 - 8592171

AN - SCOPUS:0028867792

VL - 25

SP - 215

EP - 220

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -